Evidence map›Paper›PMID 16500596›Full record

ReviewThe Lancet. Infectious diseases2006

Bacterial pneumonia vaccines and childhood pneumonia: are we winning, refining, or redefining?

Stephen K Obaro, Shabir A Madhi

Registry-linked trialAbstract readReview
In one paragraph

Review in The Lancet. Infectious diseases, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01766206 (A Multicenter Post Marketing Surveillance Study to Monitor the Safety of GlaxoSmithKline), which is not on this map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01766206 phase4completednot on this mapstarted 2013, after this paper: background citation

A Multicenter Post Marketing Surveillance Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ACWY Conjugate Vaccine(MenACWY-CRM) Administered According to the Prescribing Information to Healthy Subjects From 2 Months to 55 Years of Age in the Republic of South Korea.

TypeinterventionalSponsorGlaxoSmithKlineRan2013 to 2018Enrolled3,948ConditionsMeningococcal DiseaseArmsMenACWY-CRM (Menveo)
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Heliyon · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Impact of the pneumococcal 10-valent vaccine on reducing hospitalization for community-acquired pneumonia in children.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2016
    Article
  15. Article
  16. Article
  17. A review of the role ofPneumonia (Nathan Qld.) · 2015
    Review
  18. Risk factors for a poor outcome among children admitted with clinically severe pneumonia to a university hospital in Rabat, Morocco.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2014
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Stephen K ObaroChildren's Hospital of Pittsburgh, Pittsburgh, PA 15213-2583, USA. Stephen.Obaro@chp.edu
Shabir A Madhi

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bacterial pneumonia is a substantial cause of childhood morbidity and mortality worldwide, but determination of pathogen-specific burden remains a challenge. In less developed settings, the WHO recommended guidelines are useful for initiating care, but are non-specific. Blood culture has low sensitivity, while radiological findings are non-specific and do not discriminate between viral and bacterial causes of pneumonia. In vaccine probe studies, efficacy is dependent on the specificity of the study outcome to detect pneumonia and the impact of the vaccine on the selected outcome, and may underestimate the true burden of bacterial pneumonia. The rising incidence of antibiotic resistance, emerging respiratory pathogens, potential replacement pneumococcal disease following widespread introduction of pneumococcal polysaccharide-protein conjugate vaccine, the limited specificity of chest radiography, and the poor sensitivity of blood culture are substantial obstacles to accurate surveillance. We provide an overview of the diagnostic challenges of bacterial pneumonia and highlight the need for refining the current diagnostic approach to ensure adequate epidemiological surveillance of childhood pneumonia and the success, or otherwise, of any immunisation strategies.

Indexed as

Bacterial VaccinesPopulation SurveillanceBloodChild, PreschoolDrug Resistance, BacterialHumansImmunization ProgramsInfantInfant, NewbornPneumococcal VaccinesPneumonia, BacterialBacterial VaccinesPneumococcal Vaccines

Identifiers

PMID16500596
PMCPMC7106399

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.